These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 15964331

  • 1. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.
    Csapo Z, Benavides-Viveros C, Podder H, Pollard V, Kahan BD.
    Transplant Proc; 2005 Jun; 37(5):2032-6. PubMed ID: 15964331
    [Abstract] [Full Text] [Related]

  • 2. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 3. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 4. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL, Malek SK, Blasick TM, Pennington JR, Masker KK, Lun M, Potdar S.
    Ann Clin Lab Sci; 2007 Mar; 37(2):121-6. PubMed ID: 17522366
    [Abstract] [Full Text] [Related]

  • 5. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'alessandro AM, Sollinger HW.
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [Abstract] [Full Text] [Related]

  • 6. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M, Weppler D, Mittal N, Nishida S, Kato T, Tzakis A, Ruiz P.
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [Abstract] [Full Text] [Related]

  • 7. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [Abstract] [Full Text] [Related]

  • 8. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 9. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R.
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Campath and renal transplant rejection.
    Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK.
    Clin Transplant; 2004 Dec; 18(6):759-61. PubMed ID: 15516258
    [Abstract] [Full Text] [Related]

  • 14. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL, Malek SK, Prichard JW, Lin F, Yahya TM, Schwartzman MS, Latsha RP, Skaletsky M, Norfolk ER, Brown RE, Hartle JE, Potdar S.
    Ann Clin Lab Sci; 2004 Dec; 34(2):209-13. PubMed ID: 15228236
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 16. Tacrolimus rescue therapy for corticosteroid-resistant and polyclonal antibody-resistant kidney allograft rejections.
    Naderi GH, Mehraban D, Ganji MR, Yahyazadeh SR, Latif AH.
    Urol J; 2009 Mar; 6(1):31-4. PubMed ID: 19241339
    [Abstract] [Full Text] [Related]

  • 17. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.
    McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler BG, Starzl TE.
    J Thorac Cardiovasc Surg; 2005 Aug; 130(2):528-37. PubMed ID: 16077423
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Aug; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 20. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
    Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ.
    Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.